Literature DB >> 32661506

Prevalence of Malignancy Among Urban Black Rheumatoid Arthritis Patients.

Isabel M McFarlane1, Manjeet S Bhamra2, Abhimnayu Amarnani1, Su Yien Zhaz3, Srinivas Kolla4, Milena Rodriguez Alvarez1, George Mo1, Maya Srinivasan1, Gil Hevroni1, Talia Meisel1, Abida Hasan1, Marie S Baguidy1, Michael Hadaddin1, Adielle Melamed1, Kristaq Koci1, Nicholas Taklalsingh1, Joshy Pathiparampil1, Latoya Freeman1, Ian Kaplan1, Naureen Kabani1, David J Ozeri5, Elsie Watler1, Mosab Frefer1, Vytas Vaitkus1, Keron Matthew1, Fray Arroyo-Mercado1, Helen Lyo1, Aleksander Feoktistov1, Randolph Sanchez6, Faisal Soliman7, Felix Reyes Valdez8, Veena Dronamraju1, Michael Trevisonno1, Christon Grant1, Guerrier Clerger1, Kunfeng Sun1, Khabbab Amin1, Makeda Dawkins1, Jason Green1, Samir Fahmy3, Apoorva Jayarangaiah9, Stephen Anthony Waite4, Aaliya Burza10.   

Abstract

BACKGROUND: Rheumatoid arthritis (RA) patients have an increased risk of malignancy with postulated risk factors that include chronic inflammation, smoking and the use of immunosuppressants have been postulated as drivers of higher malignancies rates. Our study aimed to describe the prevalence and type of malignancies encountered in an urban, predominantly Black RA patient population.
METHODS: Cross sectional analysis of 1142 patients with RA diagnosis by ICD-codes of which 501 cases met the inclusion criteria for the study. Blacks accounted for 88.4% of the study population. Fifty-six patients had cancer recorded in their medical records and these cases were further reviewed for tumor type, timing of diagnosis and patient clinical characteristics.
RESULTS: The cancer prevalence was 11.2% (56/501) in our Black RA population being studied. Mean age at cancer diagnosis was 59.9 ± 5.2 for the patients who developed cancer before RA diagnosis and 58.25 ± 16.02 for those who developed malignancy after RA diagnosis. There were 18 breast cancers, 4 colon and 4 cervical cancers; for lung, multiple myeloma, thyroid, squamous cell carcinoma and pancreas there were 3 cases each; for endometrial, Non-Hodgkin's lymphoma, meningioma and prostate, 2 cases each and 1 each for urinary bladder, esophageal adenocarcinoma, lymphoma, glioblastoma, liver, Hodgkin's lymphoma, sarcoma, ovary and renal cell carcinoma. No differences were found in years of RA duration, joint erosion, joint space narrowing or SENS score except for significantly higher ESR among the cancer group and RF seropositivity in the non-cancer group.Therapeutic modalities were not significantly different between the cancer and no cancer groups.
CONCLUSION: Breast cancer was the most prevalent malignancy among our Black RA population. Further studies are needed to identify the contributing factors to the malignancy risk of breast cancer in our Black RA population and whether it is gender-related since RA is more prevalence in women.

Entities:  

Keywords:  Breast cancer; Cancer; Erosive disease; Extra-articular manifestations; Rheumatoid arthritis; Seropositive rheumatoid arthritis; Solid tumors

Year:  2020        PMID: 32661506      PMCID: PMC7357963          DOI: 10.15344/2456-8007/2020/145

Source DB:  PubMed          Journal:  Int J Clin Res Trials        ISSN: 2456-8007


  20 in total

1.  Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis.

Authors:  H A Isomäki; T Hakulinen; U Joutsenlahti
Journal:  J Chronic Dis       Date:  1978

Review 2.  Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative.

Authors:  Athan Baillet; Laure Gossec; Loreto Carmona; Maarten de Wit; Yvonne van Eijk-Hustings; Heidi Bertheussen; Kent Alison; Mette Toft; Marios Kouloumas; Ricardo J O Ferreira; Susan Oliver; Andrea Rubbert-Roth; Sander van Assen; William G Dixon; Axel Finckh; Angela Zink; Joel Kremer; Tore K Kvien; Michael Nurmohamed; Desirée van der Heijde; Maxime Dougados
Journal:  Ann Rheum Dis       Date:  2016-03-16       Impact factor: 19.103

3.  Republished: The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis.

Authors:  Jie Zhang; Lang Chen; Elizabeth Delzell; Paul Muntner; William B Hillegass; Monika M Safford; Iris Yolanda Navarro Millan; Cynthia S Crowson; Jeffrey R Curtis
Journal:  Postgrad Med J       Date:  2014-12       Impact factor: 2.401

4.  Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease.

Authors:  Elena Myasoedova; Cynthia S Crowson; Hilal Maradit Kremers; Veronique L Roger; Patrick D Fitz-Gibbon; Terry M Therneau; Sherine E Gabriel
Journal:  Ann Rheum Dis       Date:  2011-01-07       Impact factor: 19.103

5.  Reliability and sensitivity to change of the Simple Erosion Narrowing Score compared with the Sharp-van der Heijde method for scoring radiographs in rheumatoid arthritis.

Authors:  E M Dias; C Lukas; R Landewé; S Fatenejad; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2007-07-20       Impact factor: 19.103

Review 6.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Authors:  Josef S Smolen; Robert Landewé; Johannes Bijlsma; Gerd Burmester; Katerina Chatzidionysiou; Maxime Dougados; Jackie Nam; Sofia Ramiro; Marieke Voshaar; Ronald van Vollenhoven; Daniel Aletaha; Martin Aringer; Maarten Boers; Chris D Buckley; Frank Buttgereit; Vivian Bykerk; Mario Cardiel; Bernard Combe; Maurizio Cutolo; Yvonne van Eijk-Hustings; Paul Emery; Axel Finckh; Cem Gabay; Juan Gomez-Reino; Laure Gossec; Jacques-Eric Gottenberg; Johanna M W Hazes; Tom Huizinga; Meghna Jani; Dmitry Karateev; Marios Kouloumas; Tore Kvien; Zhanguo Li; Xavier Mariette; Iain McInnes; Eduardo Mysler; Peter Nash; Karel Pavelka; Gyula Poór; Christophe Richez; Piet van Riel; Andrea Rubbert-Roth; Kenneth Saag; Jose da Silva; Tanja Stamm; Tsutomu Takeuchi; René Westhovens; Maarten de Wit; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2017-03-06       Impact factor: 19.103

Review 7.  Breast cancer risk in rheumatoid arthritis: an update meta-analysis.

Authors:  Guo Tian; Jia-Ning Liang; Zhuo-Yun Wang; Dian Zhou
Journal:  Biomed Res Int       Date:  2014-10-27       Impact factor: 3.411

8.  Risk of Malignant Neoplasm in Patients with Incident Rheumatoid Arthritis 1980-2007 in relation to a Comparator Cohort: A Population-Based Study.

Authors:  Shafay Raheel; Cynthia S Crowson; Kerry Wright; Eric L Matteson
Journal:  Int J Rheumatol       Date:  2016-08-17

9.  A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis.

Authors:  Allison L Smitten; Teresa A Simon; Marc C Hochberg; Samy Suissa
Journal:  Arthritis Res Ther       Date:  2008-04-23       Impact factor: 5.156

10.  Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA).

Authors:  Maxime Dougados; Martin Soubrier; Anna Antunez; Peter Balint; Alejandro Balsa; Maya H Buch; Gustavo Casado; Jacqueline Detert; Bassel El-Zorkany; Paul Emery; Najia Hajjaj-Hassouni; Masayoshi Harigai; Shue-Fen Luo; Reka Kurucz; Gabriel Maciel; Emilio Martin Mola; Carlo Maurizio Montecucco; Iain McInnes; Helga Radner; Josef S Smolen; Yeong-Wook Song; Harald Erwin Vonkeman; Kevin Winthrop; Jonathan Kay
Journal:  Ann Rheum Dis       Date:  2013-10-04       Impact factor: 19.103

View more
  1 in total

Review 1.  Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse.

Authors:  Saeed H Manjili; Madison Isbell; Negar Ghochaghi; Tyler Perkinson; Masoud H Manjili
Journal:  Semin Cancer Biol       Date:  2021-03-27       Impact factor: 15.707

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.